Introduction {#Sec1}
============

The transformation of epithelial cells to a mesenchymal (EMT) phenotype is an important process for proper heart development. The development of the cardiac valves and septa of the heart is dependent on EMT of endocardial cells underlying the atrioventricular canal and endocardial cells underlying the outflow tract forming the endocardial cushions \[[@CR16], [@CR24], [@CR36]\]. A distinct population of cells derived from the epicardium also undergoes EMT during cardiogenesis \[[@CR30]\]. During embryogenesis, the epicardium originates from the proepicardial organ (PEO) recruited from the coelomic wall mesothelium at the venous pole of the heart. Cells derived from the PEO protrude to and cover the primitive heart tube. A part of these epicardial cells undergoes EMT, thereby forming epicardium-derived cells (EPDCs). As a result of EMT, EPDCs migrate into the subepicardium and subsequently into the myocardium \[[@CR30], [@CR51]\]. In the myocardium, EPDCs initially differentiate into interstitial fibroblasts \[[@CR30]\] and later on into smooth muscle cells and adventitial fibroblasts of the coronary vasculature \[[@CR14], [@CR50]\]. The contribution of EPDCs to heart development is not only structural, but also have a regulatory role in cardiogenesis. The mechanisms underlying this regulatory process are largely unknown, although it is likely that cell--cell communication is of importance \[[@CR30]\].

Previous in vitro studies have identified transforming growth factor beta (TGFβ) as a key regulator of EMT in the embryonic PEO and embryonic epicardium in both mouse and chicken \[[@CR5], [@CR12], [@CR16]\]. The TGFβ-regulated EMT of chicken embryonic epicardial cells is dependent on the kinase activity of the TGFβ type I receptor or activin receptor-like kinase (ALK) 5 \[[@CR5]\]. Furthermore, soluble vascular cell adhesion molecule-1 (VCAM-1) is able to inhibit TGFβ-induced EMT \[[@CR16]\]. Examination of the expression patterns of other growth factors present during embryonic development implies a role for fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) in epicardial EMT \[[@CR6], [@CR45]\]. Interestingly, the aforementioned roles of epicardial cells and EPDCs do not seem to be restricted to embryonic development. In the adult heart, the epicardium is a simple squamous epithelium, which functions as a smooth surface on which the heart slides in the pericardial cavity during contraction \[[@CR30]\]. Over the last few years, several studies have focused on the role of adult epicardium and EPDCs in heart repair. Recently, we demonstrated that human adult spindle-shaped EPDCs, injected into the infarcted myocardium, preserved cardiac function and reduced remodeling both early and late after the onset of infarction \[[@CR52]\]. These findings suggest that EPDCs could be a suitable cell source for cardiac cell therapy. Interestingly, recent in vivo studies showed that endogenous epicardium was reactivated after a myocardial infarction, thereby re-expressing embryonic markers such as *raldh2*, *Tbx18* and *WT1* \[[@CR19], [@CR29], [@CR31], [@CR44], [@CR52]\]. Furthermore, re-activated epicardial cells proliferate and are able to undergo EMT, and after they migrate into the injured myocardium contribute to cardiac regeneration \[[@CR19], [@CR29], [@CR31], [@CR44], [@CR52]\]. These studies suggest that adult epicardium is a dynamic tissue, which is still able to generate EPDCs that can contribute to the adult ventricular wall. More insight into the signals that direct the process of EMT in adult epicardial cells would be beneficial for endogenously regulated cell-based cardiac repair, thereby providing the opportunity to investigate the possibilities to bypass the need for cell transplantation by stimulating repair by endogenous cells \[[@CR33]\].

Therefore, the aim of this study was to gain more insight into the EMT process of human adult epicardial cells and to determine which factors are involved in EMT of human adult epicardium. We characterized human adult epicardial cells in vitro before and after EMT. Here, we describe that the cobblestone-like VCAM-1 expressing EPDCs (cEPDCs) upon TGFβ stimulation undergo specific morphological changes including the loss of epithelial characteristics. Spindle-shaped EPDCs (sEPDCs) have the appearance of a smooth muscle-like morphology and express endoglin, while VCAM-1 expression is inhibited in an ALK5-dependent manner. Furthermore, we show that WT1 is a repressor of the EMT process in human adult epicardial cells. Taken together with the expression patterns of TGFβ and WT1 after myocardial infarction, these new insights into the process of EMT in human adult epicardial cells may help in the development of therapies for cardiac repair.

Materials and methods {#Sec2}
=====================

Human specimens {#Sec3}
---------------

All experiments with human tissue specimens were carried out according to the official guidelines of the Leiden University Medical Center and with the approval of the institutional ethical committee.

Harvesting and preparation of human epicardial cells {#Sec4}
----------------------------------------------------

Cultures of human epicardial cells with an epithelium-like morphology, also referred to as cobblestone-like EPDCs (cEPDCs), were prepared as described previously \[[@CR49]\]. Briefly, EPDCs were cultured from the right atrial appendages excised during cardiac surgery from several adult patients. The layer of epicardium was stripped and minced into small pieces. The tissue pieces were cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM low glucose) and medium 199 (M199) containing 100 U/ml penicillin, 100 μg/ml streptomycin, 10% inactivated fetal calf serum (FCSi) (all from Invitrogen, Paisly, UK), and 2 ng/ml basic fibroblast growth factor (bFGF) (Sigma-Aldrich, St. Louis, USA). The addition of bFGF stimulated outgrowth of cells from the tissue pieces and the proliferation of the cells. When the outgrowth of the epicardial cells was confluent, the cells were detached from the bottom of the culture dish with trypsin/EDTA (Invitrogen) solution. The cells were seeded in high density and cultured in a 1:1 mixture of DMEM and M199 supplemented with 100 U/ml penicillin, 100 μg/ml streptomycin and 10% FCSi to maintain the epithelium-like morphology (cobblestone-like EPDCs, cEPDCs). The medium was refreshed every 3 days. Stimulation experiments were performed with cEPDCs from passage (P) 2--4 of three different patients. In total, we used isolations from nine different right atrial appendages.

The purity of the human cEPDC cultures was certified with immunohistochemical staining for Wilms tumor-1 protein (WT1) (Calbiochem, San Diego, USA) at a dilution of 1:50.

For the in vitro stimulation experiments, cells were plated at a density of 20,000 cells/cm^2^ and were allowed to attach for 24 h prior to the addition of growth factor or inhibitor.

Addition of growth factors or inhibitors {#Sec5}
----------------------------------------

The medium was supplemented with the growth factors and inhibitors 24 h after seeding of the human adult cEPDCs. Growth factors TGFβ3 (1 ng/ml) (R&D Systems Inc., Minneapolis, USA) and sVCAM-1 (100 ng/ml) (R&D Systems) or small molecule inhibitors SB431542 (iALK5, 10 μM) (Sigma-Aldrich), α-Endoglin antibody (0.5 μg/ml) (R&D Systems) and Y27632 (iROCK 2.33 μg/ml) (Calbiochem) were used. At 48 h after the addition of stimulators, cells were used for further analysis by immunohistochemical analysis, qPCR, Western blot analysis and an MTT assay.

Immunophenotyping {#Sec6}
-----------------

The surface antigen expression profiles of epicardial cells (cEPDCs) and epicardium-derived cells (sEPDCs) were determined by flow cytometry as described previously \[[@CR49]\]. The antibodies used for flow cytometric analysis are listed in Table [1](#Tab1){ref-type="table"}.Table 1Antibodies used for flow cytometry and immunohistochemistryAntigenSourceCloneIsotypeLabelSpeciesβ-CateninBD14IgG1--Mouseα/β-TubulinCellSig------RabbitαSMASA--IgG2a--MouseCD31CLBHEC/75IgG1FITCMouseCD34BD8G12IgG1PEMouseCD44BDG44-26 C26IgG2bPEMouseCD46BDE4.3IgG2aFITCMouseCD90BD5E10IgG1FITCMouseCD105BioSN6IgG1PEMouseCD106BD51-10C9IgG1PEMouseEndoglinHM------RabbitGAPDHMP6C5IgG1MouseId1SCRabbitPai-1SCRabbitpSmad1HM------RabbitpSmad2HM------RabbitVE-cadherinSCF8IgG1--MouseVimentinSAV9IgG1Cy3MouseWT1CA------RabbitGoat IgGMP----Alexa Fluor 568RabbitMouse IgDako----FITCRabbitMouse IgBD----FITCGoatMouse IgG1BDX56IgG1PERatRabbit IgGMP----Alexa Fluor 568GoatMouse IgG2aMP--IgG2aAlexa Fluor 488GoatRabbit IgGVL----BiotinGoatMouse IgGVL----BiotinHorseAll antibody preparations were used at the concentrations recommended by the suppliers. For an explanation of the abbreviations of the antigens, see the main text of the paper*BD* BD Biosciences, *Bio* Biocarta, *CA* Calbiochem, *CLB* Sanquin, *CellSig* Cell Signaling, *Dako* Dako Cytomation, *HM* homemade, *MP* Molecular Probes, *SA* Sigma-Aldrich, *SC* Santa Cruz, *VL* Vector Labs, *FITC* fluorescein isothiocyanate, *PE* phycoerythrin

Immunohistochemical analysis {#Sec7}
----------------------------

cEPDCs were cultured on glass chamber slides and, 48 h after stimulation, slides were subjected to immunohistochemical analysis \[[@CR49]\]. Briefly, after fixation and permeabilization with 0.1% Triton, slides were incubated overnight with primary antibodies. The details of the antibodies are listed in Table [1](#Tab1){ref-type="table"}. To investigate their morphology, the cells were immunofluorescently stained for β-catenin, phalloidin and α-smooth muscle actin (αSMA). Staining for β-catenin was performed overnight to detect cells with epithelial morphology, using an anti mouse FITC labeled secondary antibody. Prior to incubation (1 h) with phalloidin directly labeled with Rhodamine, cells were blocked with 3% BSA/PBST for 45 min. For immunofluorescence, the nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (diluted 1:1,000 in PBS). Finally, the slides were mounted with Vectashield (Vector, Burlingame, USA). Examination of the slides was performed using a fluorescence microscope and light microscope equipped with a digital camera (Diagnostics, RT3 slider, Sterling Heights, MI, USA).

Cells that were labeled with the antibody against α-smooth muscle actin (αSMA) were incubated with 5% bovine serum albumin (BSA, fraction V) in PBS (30 min) prior to the primary antibody, to block non-specific binding, Subsequently, cells were incubated in modified NET-gel (50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.25% gelatin and 0.05% nonidet P40) with 0.5% BSA and an appropriate secondary antibody (see Table [1](#Tab1){ref-type="table"}), carried out for 2 and 1 h at room temperature, respectively. The slides were mounted with Mowiol and analyzed using a fluorescence microscope (Zeiss Inc, New York, USA).

Western blotting {#Sec8}
----------------

For total protein extraction of cEPDCs under the described culture conditions, cells were trypsinized and the cell pellet was lysated in a sample buffer (SB) containing 10% SDS, 20% glycerol, 0,1% bromophenol blue, 5% β-mercapto-ethanol and Tris--HCl, pH 6.8. Homogenates were size-fractionated on 10% PAGE gels and transferred to Hybond PVDF membranes. After blocking non-specific binding sites, membranes were incubated overnight with the anti-pSmad1 (previously described by Goumans et al. \[[@CR22]\]), pSmad2 (previously described by Goumans et al. \[[@CR22]\]), inhibitor of differentiation 1 (Id1), plasminogen activator inhibitor-1 (Pai-1), endoglin (previously described by Lebrin et al. \[[@CR27]\]) and αSMA antibodies (Table [1](#Tab1){ref-type="table"}) followed by incubation with a horseradish peroxidase (HRP)-labeled secondary antibody (goat anti-rabbit or rabbit anti-goat) for 1 h. A competitive Western blot for GAPDH and α/β-tubulin was performed to correct differences in protein concentration. Chemiluminescence was induced by ECL Advanced Detection reagent and detected by exposure to Hyperfilm ECL.

MTT assay {#Sec9}
---------

The total number of living cells as a measure for proliferation and viability was determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT; Sigma-Aldrich) assay (*n* = 3). Cells were seeded in quatro in 95-well plates with 20,000 cells/cm^2^ and stimulated as described previously. In addition, the different cultures were incubated for 3 h with MTT (50 μg/well) in fresh culture medium. The medium was removed and crystallized formazan dye in the cells was solubilized by adding dimethylsulfoxide (DMSO). Absorbance was measured at 540 nm using 690 nm as reference. Quantification was carried out by comparison absorbance after 48 h of stimulation with absorbance before stimulation.

RNA interference {#Sec10}
----------------

Endoglin was knocked down using shRNA pTER technology \[[@CR46]\], targeting the following 19-nucleotide sequence: 5′-GAAAGAGCTTGTTGCGCA-3′ \[[@CR10]\]. Oligonucleotides were cloned into the pTER vector under the control of the H1-RNA promoter. H1-RNA promoter and targeting sequence were subsequently transferred to the pRRL-CMV-GFP vector using *Pst*I and *Xho*I sites (opposite orientation of CMV-GFP cassette). The plasmid was then used for lentivirus production. cEPDCs were transduced with lentivirus expressing shRNAs that specifically target human endoglin, as described above, and control GFP virus. After 6 h of culturing in the presence of 8 μg/ml polybrene, the medium was refreshed. The day after the cells were plated in six-well plates and 2 days after transduction, cells were stimulated with TGFβ3 (1 ng/ml) comparable to the other stimulation experiments.

mRNA isolation and quantitative RT-PCR analysis {#Sec11}
-----------------------------------------------

Total RNA from cEPDCs stimulated as described was isolated using TriPure (Roche, Almere, The Netherlands) following the manufacturer's protocol. cDNA was synthesized from 750 ng RNA per sample, using iScript cDNA synthesis kit (Fermentas, Leon-Rot, Germany). cDNA samples were subjected to quantitative RT-PCR (qRT-PCR) by using SYBRgreen (Roche) and a primer concentration of 10 μM. Primers were designed with Primer3 and qPrimerDepot (htp://primerdepot.nci.nih.gov/). Primer sequences and annealing temperatures are available on request. qRT-PCR was performed for the following factors: *WT1* isoform A, *WT1* isoform D, *TGFβ1*, *2*, and *3*, *ALK1*, *ALK5*, *VCAM*-*1*, *E*-*cadherin*, *endoglin* and *Snai1*. qRT-PCR reactions were run on a 7900HT Applied Biosystems. PCR conditions were: 10 min. at 95°C followed by 40 cycles of 30 s at 95°C, 30 s annealing temperature (60°C) and 30 s at 72°C. All samples were corrected for input based on housekeeping gene *β-actin*, which was not influenced by the different culture conditions (data not shown) and normalized to unstimulated conditions.

Statistics {#Sec12}
----------

All data of the volume measurements are presented as average ± SEM. The PCR data were quantified using the 2^−∆∆Ct^ method, by comparing signal of the sh-RNA treated groups with that of the control group, both relative to an internal control, *β-actin*. Analysis of the qRT-PCR data was performed with T test. Significance was assumed when *P* \< 0.05 using SPSS 16.0 software program (SPSS Inc. Chicago, USA). Graphics of statistical analysis were composed by Graphpad software. For simplification of the interpretation of the data, in all graphs representing the expression of mRNA of epithelial and EMT markers the fold inductions of the control and TGFβ3-stimulation were displayed.

Results {#Sec13}
=======

Analysis of cell surface marker profile {#Sec14}
---------------------------------------

We expanded human cEPDCs from several atrial appendages and certified the purity of the cultures by WT1 staining (Fig. [1](#Fig1){ref-type="fig"}a, b). In both cEPDCs (Fig. [1](#Fig1){ref-type="fig"}a) and sEPDCs (Fig. [1](#Fig1){ref-type="fig"}b), WT1 was predominantly localized in the nuclei. The surface antigen profile of cEPDCs and sEPDCs was analyzed by flow cytometry (Table [1](#Tab1){ref-type="table"}). As previously reported \[[@CR49]\], sEPDCs abundantly expressed the TGFβ co-receptor endoglin (CD105) at their plasma membrane (Fig. [1](#Fig1){ref-type="fig"}c, d). The surface of cEPDCs was not decorated with endoglin, but contained substantial amounts of VCAM-1 (CD106) (Fig. [1](#Fig1){ref-type="fig"}c--e). For the other surface markers that were tested, cEPDCs and sEPDCs yielded similar results, i.e., hyaluronate receptor (CD44), membrane cofactor protein of the complement system (MCP; CD46) and major T-cell antigen (Thy1; CD90) were present. Neither cEPDCs nor sEPDCs expressed the hematopoietic marker CD34 or endothelial markers such as platelet-endothelial cell adhesion molecule-1 (PECAM-1; CD31) and vascular endothelial (VE)-cadherin at their cell surface (Fig. [1](#Fig1){ref-type="fig"}c).Fig. 1Surface marker profile of human adult epicardial cells. EPDC cultures were stained using WT1 to certify the purity of the culture (**a**, **b**). Flow cytometric analysis of cultured adult human EPDCs before (cEPDCs) and after EMT (sEPDCs) was performed (**c**). Histograms of endoglin (CD105) (**d**) and VCAM-1 (CD106) (**e**) are shown with isotype control (*dashed line*) and the specific signal (*solid line*). *Scale bar* 20 μm

TGFβ-signaling in epicardial cells {#Sec15}
----------------------------------

Among the many molecules that regulate the EMT process in many different organs, there is one common element among them involving the TGFβ superfamily. Therefore, we examined the expression of the TGFβ type I receptors, ALK1 and ALK5, and found both ALK1 and ALK5 expressed in cEPDCs (Online Resource 1 and Fig. [2](#Fig2){ref-type="fig"}a) confirming that human cEPDCs are able to respond to TGFβ. The patterns and abbreviations used in the graphs are depicted in Box 1 in [Appendix](#Sec30){ref-type="sec"}. Interestingly, the addition of TGFβ increased the expression of *ALK5* mRNA by 1.6-fold (*P* \< 0.05) (Fig. [2](#Fig2){ref-type="fig"}a), while the expression of *ALK1* decreased by 30% (*P* \< 0.05) (Online Resource 1). Furthermore, qRT-PCR confirmed the presence of *TGFβ1*, *TGFβ2* and *TGFβ3* transcripts in the human adult cEPDCs (Online Resource 2).Fig. 2Western blot and qRT-PCR analysis. Gene expression of cEPDCs (control; C) and cEPDCs treated with 1 ng/ml TGFβ3 (T) showed that the expression of *ALK5* was increased by TGFβ (**a**). Western blot analysis of protein samples isolated from cEPDCs stimulated in the presence or absence of 1 ng/ml TGFβ3 and α-Endoglin probed for Pai-1 (**b**). As a loading control, α/β-tubulin was used (**b**). Western blot analysis of αSMA and endoglin in epicardial cells stimulated by sVCAM-1 (100 ng/ml) and α-Endoglin (0.5 μg/ml) independent or simultaneously with TGFβ3 (1 ng/ml) (**c**, **d**). GAPDH was used as a loading control in this experiment (**c**, **d**). Gene expression of cEPDCs and cEPDCs treated with TGFβ3, iALK5 and both simultaneously. Treatment with TGFβ showed significant decrease in epithelial markers and increase in EMT marker *Snai1*, which is dependent on ALK5 kinase activity (**e**). \**P* \< 0.05 versus control, ^\#^*P* \< 0.05 versus TGFβ3 stimulation. For patterns and abbreviations see Box 1 in [Appendix](#Sec30){ref-type="sec"}

To test whether the TGFβ-signaling pathway is functional in epicardial cells, we analyzed the expression of two defined downstream targets using Western blot analysis, Id1 and Pai-1 as downstream targets of pSmad1/5 and pSmad2/3, respectively. We were not able to detect any Id1 protein 2 days after TGFβ stimulation (data not shown), although Pai-1 was present in all samples (Fig. [2](#Fig2){ref-type="fig"}b). The expression of Pai-1 was increased after TGFβ stimulation and markedly reduced if the ALK5 kinase inhibitor was added to the medium (Fig. [2](#Fig2){ref-type="fig"}b).

TGFβ causes loss of epithelial character {#Sec16}
----------------------------------------

To determine whether the TGFβ-signaling pathway is involved in EMT of human adult epicardial cells, we examined the effect of TGFβ stimulation on the epithelial character of these cells (Fig. [3](#Fig3){ref-type="fig"}a, b). Incubating cEPDCs with TGFβ for 48 h resulted in elongation of the cells (Fig. [3](#Fig3){ref-type="fig"}b), which is indicative for EMT. To further confirm EMT, we stained with the epithelial marker β-catenin to mark cell--cell junctions and phalloidin to visualize filamentous actin. In untreated cells, β-catenin was localized in cell junctions (adherens junctions) and actin filaments were associated with these junctions (cortical actin filaments) (Fig. [3](#Fig3){ref-type="fig"}a2,3). When stimulated with TGFβ, the cEPDCs showed decreased expression and cytoplasmic redistribution of β-catenin (Fig. [3](#Fig3){ref-type="fig"}b2), while the actin filaments were clearly visible across the cells (stress fibers) (Fig. [3](#Fig3){ref-type="fig"}b3). These changes were consistent with the cellular events known to occur during EMT in which dissolution of organized cell junctions and reorganization of actin into stress fibers is needed to allow actin-myosin based contraction. TGFβ stimulation also caused increased staining of αSMA (Fig. [3](#Fig3){ref-type="fig"}b4), which was confirmed by Western blot analysis (Fig. [2](#Fig2){ref-type="fig"}c). Although αSMA expression increased after TGFβ stimulation, the cells still expressed WT1, demonstrating their undifferentiated state. To further explore this apparent loss of epithelial character, we examined the mRNA expression of *E*-*cadherin*, *VCAM*-*1* and *Snai1* by qRT-PCR (Fig. [2](#Fig2){ref-type="fig"}e) and the expression of endoglin by Western blot (Fig. [2](#Fig2){ref-type="fig"}c). Quantitative analysis of the epithelial markers E-cadherin and VCAM-1 after incubation with TGFβ showed significant decrease in *VCAM*-*1* expression by 97% (*P* \< 0.05), while the expression of *E*-*cadherin* did not change significantly (Fig. [2](#Fig2){ref-type="fig"}e). The expression of *Snai1*, best known for its induction of phenotypic changes, increased by 1.5-fold (Fig. [2](#Fig2){ref-type="fig"}e). Western blot analysis revealed that the expression of endoglin was not altered by the addition of TGFβ (Fig. [2](#Fig2){ref-type="fig"}c). These data show that in EPDCs, TGFβ causes loss of epithelial characteristics and induces the onset of differentiation into a smooth muscle cell phenotype.Fig. 3TGFβ-stimulated EMT is dependent on ALK5 kinase activity. Transforming growth factor (TGFβ) induces epithelial-to-mesenchymal transformation (EMT) in human adult epicardial cells, and ALK5 is required for the effects of TGFβ. Epicardial cells were treated with 1 ng/ml TGFβ3, 10 μM SB431542 (iALK5) and ALK5 kinase inhibitor for 48 h before fixation. Untreated epicardial cells display an epithelial phenotype (**a**) accompanied with expression of β-catenin (**a2**) and phalloidin (**a3**) at the cell--cell borders. Cells incubated with TGFβ are elongated, have lost β-catenin expression and phalloidin was visualized across the cells in stress fibers (**b1**--**3**). Cells treated with TGFβ express αSMA consistent with a smooth muscle phenotype (**b4**). In the presence of iALK5, cells display an epithelial phenotype (**c**) consistent with the untreated cells (**a**). Cells treated simultaneously with TGFβ and iALK5 retain expression of β-catenin at the cell border and no phalloidin staining across the cells is present (**d**). All untreated and treated cells express WT1 (**a5**--**d5**). ×100 in **a1**--**d1**. *Scale bar* 20 μm

ALK5 is required and sufficient for loss of epithelial character {#Sec17}
----------------------------------------------------------------

To determine whether the TGFβ-induced morphological changes which we observed in human adult epicardial cells is ALK5 dependent, we incubated cEPDCs with TGFβ in the presence or absence of the ALK5 kinase inhibitor (iALK5), SB431542, and observed that cEPDCs stimulated in the presence of iALK5 preserve their epithelial appearance. qRT-PCR analysis confirmed this epithelial phenotype, as the expression of *E*-*cadherin* mRNA was increased by 107% (*P* \< 0.05) in the presence of iALK5, although the expression of *VCAM*-*1* decreased by 70% (*P* \< 0.05) (Fig. [2](#Fig2){ref-type="fig"}e). Western blot analysis showed that the addition of iALK5 markedly reduced endoglin levels (Fig. [2](#Fig2){ref-type="fig"}c). Cells incubated simultaneously with TGFβ and iALK5 did not elongate (Fig. [3](#Fig3){ref-type="fig"}d), and β-catenin and phalloidin were persistent at the cell junctions (Fig. [3](#Fig3){ref-type="fig"}d2,3). The decrease in expression of *VCAM*-*1* and the increase of *Snai1* mRNA by TGFβ was completely neutralized when iALK5 was added (Fig. [2](#Fig2){ref-type="fig"}e). Simultaneous addition of TGFβ and iALK5 markedly decreased the protein level of endoglin, comparable to the addition of iALK5 alone (Fig. [2](#Fig2){ref-type="fig"}c).

RhoA in epicardial EMT {#Sec18}
----------------------

TGFβ is known to activate several downstream pathways independent of Smad-signaling, e.g., via RhoA-mediated activation \[[@CR12]\]. To address the potential role of RhoA in TGFβ-stimulated loss of epithelial character in human adult epicardial cells, we inhibited the p160 rho kinase, a downstream effector of RhoA. cEPDCs were treated with Y27632, a specific inhibitor of p160-ROCK (rho-associated coiled-coil kinase) (iROCK) in the absence or presence of TGFβ3. The addition of iROCK caused elongation of the cells, which was accompanied with the decrease of β-catenin and phalloidin at the cell junctions (Online Resource 3). Stress fibers were not detected by phalloidin and also staining for αSMA was below detection levels (Online Resource 3). Simultaneous addition of TGFβ and iROCK resulted in similar morphological changes as addition of iROCK alone, although stress fibers became visible across the cells (Online Resource 3). These data show that p160 rho kinase activity does not mediate the expression of smooth muscle cell markers in response to TGFβ.

VCAM-1 and endoglin alter the cytoskeleton of human adult EPDCs {#Sec19}
---------------------------------------------------------------

Analysis of the cell surface marker profile showed spatiotemporal differences in VCAM-1 and endoglin expression. As the soluble form of the α4β1-integrin ligand VCAM (sVCAM) stimulates change in epicardial cells which restrict EMT and the fact that endoglin is part of the TGFβ-receptor complex \[[@CR4], [@CR16]\], the question raised is whether VCAM-1 and endoglin are involved in the EMT process in human adult epicardial cells. To determine the cellular mechanism through which VCAM-1 inhibits epicardial EMT, we treated human adult cEPDCs with sVCAM-1 for 48 h and did not observe morphologic changes of the cells (Fig. [4](#Fig4){ref-type="fig"}b). The expression of β-catenin mRNA was increased in cells stimulated with sVCAM-1 (Fig. [4](#Fig4){ref-type="fig"}b2), while there was a decrease in cortical actin filaments (Fig. [4](#Fig4){ref-type="fig"}b3). qRT-PCR for the epithelial markers *E*-*cadherin* and *VCAM*-*1* and the EMT marker *Snai1* showed that treatment with sVCAM-1 did not significantly change their mRNA expression (Fig. [4](#Fig4){ref-type="fig"}d).Fig. 4sVCAM-1 inhibits cell shape changes in human adult epicardial cells treated with TGFβ3. Unstimulated cells (**a**) and stimulated with sVCAM-1 (100 ng/ml) (**b**) and simultaneously with TGFβ3 (1 ng/ml) and sVCAM-1 (100 ng/ml) (**c**) are stained for β-catenin (**a2**--**c2**) and with phalloidin to visualize filamentous actin (**a3**--**c3**). Onset of differentiation into smooth muscle cells was visualized by staining for αSMA (**a4**--**c4**) and the state of differentiation was visualized by WT1 (**a5**--**c5**). The process of EMT was confirmed by qRT-PCR (**d**) analysis for epithelial and EMT markers. ×100 in **a1**--**c1**. *Scale bar* 20 μm. \**P* \< 0.05 versus control, ^\#^*P* \< 0.05 versus TGFβ3 stimulation, ^\$^*P* \< 0.05 stimuli versus simultaneous TGFβ3/stimuli. For patterns and abbreviations see Box 1 in [Appendix](#Sec30){ref-type="sec"}

Since sVCAM-1 might stimulate the preservation of intercellular adhesion, we simultaneously treated cEPDCs with TGFβ and sVCAM-1. Remarkably, the presence of sVCAM-1 not only prevented the morphologic changes of the cells (Fig. [4](#Fig4){ref-type="fig"}c), but also prevented the formation of filamentous actin (Fig. [4](#Fig4){ref-type="fig"}c3) although there was alteration of β-catenin in cell junctions (Fig. [4](#Fig4){ref-type="fig"}c2). Strikingly, qRT-PCR data showed that the expression of *E*-*cadherin* and *Snai1* both increased significantly by 1.8 and 6.2 times, respectively, while the expression of *VCAM*-*1* mRNA decreased significantly (83%) in the presence of TGFβ and sVCAM-1 (Fig. [4](#Fig4){ref-type="fig"}d). These data show that sVCAM-1 is able to restrict TGFβ-stimulated EMT.

Endoglin is a co-receptor modulating the TGFβ signal transduction pathway \[[@CR13], [@CR43]\] and is markedly present at the surface of the epicardial cells after EMT. Endoglin has been postulated to be involved in the cytoskeletal organization affecting cell morphology and migration \[[@CR36]\]. To understand if and how endoglin functions in the EMT process, cEPDCs were incubated with an α-Endoglin antibody (Fig. [5](#Fig5){ref-type="fig"}a). α-Endoglin did not induce morphologic changes of cEPDCs. In cells treated with α-Endoglin, the expression of β-catenin increased, which was accompanied with increased expression of *E*-*cadherin* and *VCAM*-*1* by 74 and 64% (*P* \< 0.05), respectively (Fig. [5](#Fig5){ref-type="fig"}b, c). Interestingly, Western blot analysis showed that addition of α-Endoglin increased the protein levels of endoglin in human EPDCs (Fig. [2](#Fig2){ref-type="fig"}c). The α-Endoglin antibody was not able to prevent the morphologic changes induced by TGFβ, as evident by decreased β-catenin expression and an increased expression of phalloidin (Fig. [5](#Fig5){ref-type="fig"}b). qRT-PCR data showed a decrease in mRNA levels of *VCAM*-*1* by 96% and increase of *Snai1* by 118% (Fig. [5](#Fig5){ref-type="fig"}c). These data show that incubating human EPDCs with an endoglin antibody does not affect TGFβ-induced EMT.Fig. 5Inhibition of endoglin expression cannot block the process of TGFβ-stimulated EMT. Blocking of endoglin increased the expression of epithelial markers (**a**, **c**). In simultaneous treatment of epicardial cells with TGFβ and α-Endoglin, the decrease in epithelial and increase in mesenchymal and EMT markers stimulated by TGFβ could not be prevented (**a**--**c**). \**P* \< 0.05 versus control, ^\$^*P* \< 0.05 stimuli versus simultaneous TGFβ3/stimuli. ×100 in **a1**--**b1.***Scale bar* 20 μm. For patterns and abbreviations see Box 1 in [Appendix](#Sec30){ref-type="sec"}

EMT in EPDCs is accompanied by a strong induction of endoglin. To ensure that the inability of the antibody to block TGFβ-induced EMT is not caused by the high levels of endoglin, we analyzed the effect of endoglin knockdown on TGFβ-induced EMT. Human adult cEPDCs were transduced with a lentivirus expressing an shRNA for human *endoglin* (*shEndoglin*) or eGFP as a control (Fig. [6](#Fig6){ref-type="fig"}a1, b1). Transduction of cEPDCs with shRNAs did not affect the epithelial morphology (Fig. [6](#Fig6){ref-type="fig"}a2, b2) and also the TGFβ-induced morphological changes (Fig. [6](#Fig6){ref-type="fig"}a3, b3). EMT was confirmed by qRT-PCR showing a decrease in *VCAM*-*1* (Fig. [6](#Fig6){ref-type="fig"}e) and increase of *Snai1* mRNA (Fig. [6](#Fig6){ref-type="fig"}f). Although endogenous endoglin levels were reduced on both mRNA (78%, *P* \< 0.05) and protein levels (Fig. [6](#Fig6){ref-type="fig"}c, d), the addition of TGFβ3 was able to induce endoglin at both the mRNA (2.2 times, *P* \< 0.05) and protein levels in *shEndoglin*-transduced cells (Fig. [6](#Fig6){ref-type="fig"}c, d). These data show that knockdown of *endoglin* is not able to restrict TGFβ-stimulated EMT and increase in endoglin expression.Fig. 6Knockdown of endoglin expression cannot block the process of TGFβ-stimulated EMT. Transduction of epicardial cells with lentivirus expression shRNAs for control GFP virus (Control) and human endoglin (shEndoglin) was visualized by the expression of GFP (**a1**, **b1**) and did not affect the cell morphology (**a2**, **b2**). Addition of TGFβ caused morphological changes in both shEndoglin-transduced cEPDCs and control (**a3**, **b3**). qRT-PCR (**c**) and Western blot (**d**) analysis showed reduction of endogenous endoglin expression after transduction (**c**, **d**). Addition of TGFβ caused increase in endoglin expression in both transduced and control epicardial cells. Analysis of epithelial marker *VCAM*-*1* (**e**) and EMT marker *Snai1* (**f**) showed that knockdown of *endoglin* could not prevent the effects of TGFβ on these markers. ×100 in **a1**--**c2**. \**P* \< 0.05 versus control, ^\#^*P* \< 0.05 TGFβ3 stimulation versus nonstimulated. *C* control, *T* TGFβ3; *shE* shEndoglin, *shTE* TGFβ3/shEndoglin

Role of WT1 in the process of EMT {#Sec20}
---------------------------------

EMT is the onset for migration and/or differentiation of the epicardium. Therefore, we determined the differentiation state of the treated epicardial cells by analyzing the presence of WT1. WT1 is only expressed in epicardial cells if they are in an undifferentiated state. Immunohistochemistry shows that all treated epicardial cells express WT1 (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}). To determine if the level of WT1 expression is affected by the treatment of the cells with several stimulators and inhibitors, we performed qRT-PCR analysis of *WT1* mRNA expression. We observed decrease in *WT1* expression in the presence of TGFβ by 68% (*P* \< 0.05) (Fig. [7](#Fig7){ref-type="fig"}a). Simultaneous addition of TGFβ with either iALK5, sVCAM-1 or α-Endoglin caused a decrease in *WT1* expression by 45, 35 and 78%, respectively (Fig. [7](#Fig7){ref-type="fig"}a). Addition of iALK5, sVCAM-1 or α-Endoglin alone did not change the expression of *WT1* significantly (Fig. [7](#Fig7){ref-type="fig"}a).Fig. 7Role of WT1 in the EMT process of human adult epicardial cells. Quantification of *WT1* isoform A mRNA expression in human adult epicardial cells decreased after treatment with TGFβ3 (**a**). Knockdown of *WT1* by shRNA results in loss of epithelial character of epicardial cells (**b**--**d**). Quantification of *WT1* mRNA expression was significantly reduced in epicardial cells after knockdown of *WT1* (*P* \< 0.05) (**e** and Online Resource 3). The expression of epithelial markers *E*-*cadherin* (**f**), *α4*-*integrin* (**g**) and *VCAM*-*1* (**h**) mRNA was decreased in epicardial cells after knockdown of WT1 (*P* \< 0.05). The expression of EMT marker *Snai1* increased significantly after knockdown of WT1 (*P* \< 0.05) (**i**). WT1 knockdown caused a significant decrease in *Pdgfrα* mRNA expression (*P* \< 0.05) (**j**). \**P* \< 0.05 versus control, ^\#^*P* \< 0.05 versus TGFβ3 stimulation, ^\$^*P* \< 0.05 stimuli versus simultaneous TGFβ3/stimuli. For patterns and abbreviations see Box 1 in [Appendix](#Sec30){ref-type="sec"}

As WT1 is high in the presence of factors preventing EMT and low in the presence of EMT stimulating factors, we explored the role of WT1 in the process of EMT. Therefore, we transduced human adult cEPDCs with shRNAs for *WT1* (*shWT1*). Morphological analysis showed elongation of the WT1 knockdown cells (Fig. [7](#Fig7){ref-type="fig"}d) when compared with the control and noncoding shRNA-transduced cells (Fig. [7](#Fig7){ref-type="fig"}b, c). qRT-PCR analysis for *WT1* after transduction showed that *shWT1* transduction decreased the mRNA expression of the *WT1* isoform A and isoform D by 79% (*P* \< 0.05) (Fig. [7](#Fig7){ref-type="fig"}e) and 83% (*P* \< 0.05) (Online Resource 4), respectively. The observed elongation of the epicardial cells was accompanied with a decrease in the epithelial marker *E*-*cadherin* by 65% (Fig. [7](#Fig7){ref-type="fig"}f). The expression of *α4*-*integrin* and its ligand *VCAM*-*1* (Fig. [7](#Fig7){ref-type="fig"}g, h) decreased by 14 and 35% (*P* \< 0.05), respectively, and the EMT marker *Snai1* was increased by 98% after transduction of shWT1 (*P* \< 0.05) (Fig. [7](#Fig7){ref-type="fig"}i).

Role of platelet-derived growth factors in the process of EMT {#Sec21}
-------------------------------------------------------------

The platelet-derived growth factor (PDGF)-signaling pathways were found to have a crucial role in EMT during cancer progression, since PDGF-A and its receptor PDGFR-α were highly elevated and secretion of PDGF-A was induced upon TGFβ-induced EMT \[[@CR20], [@CR23]\]. We previously showed that there was a relation between WT1 and Pdgfrα, which may affect the process of EMT \[[@CR7]\]. Interestingly, mRNA expression of *WT1* in human adult EPDCs is increased after *shPdgfrα* transduction \[[@CR7]\]. Furthermore, *WT1* knockdown increased the expression of *Pdgfrα* mRNA by 85% (*P* \< 0.05) (Fig. [7](#Fig7){ref-type="fig"}j). To address the potential role of PDGFR-α and its ligand PDGF-A in TGFβ-stimulated loss of epithelial character and the onset of smooth muscle differentiation in human epicardial cells, we analyzed the expression of *Pdgfa* (Fig. [8](#Fig8){ref-type="fig"}a) and *Pdgfrα* (Fig. [8](#Fig8){ref-type="fig"}b) mRNA after the addition of the different stimulators and inhibitors. In response to TGFβ3, the expression of *Pdgfa* increased by 1.5-fold, while that of *Pdgfrα* decreased by 70% (*P* \< 0.05) (Fig. [8](#Fig8){ref-type="fig"}). iALK5 inhibited the effect of TGFβ on the expression of *Pdgfa* and *Pdgfrα* (Fig. [8](#Fig8){ref-type="fig"}). The additions of sVCAM-1 and α-Endoglin were not able to influence the effect TGFβ had on the expression of *Pdgfα* and *Pdgfrα*.Fig. 8PDGF-signaling in EMT. Quantification of *Pdgfa* (**a**) and *Pdgfrα* (**b**) mRNA expression in human adult epicardial cells. The expression of *Pdgfa* increased (**a**) significantly (*P* \< 0.05) after treatment with TGFβ3 in contrast to decrease of *Pdgfrα* expression (**b**) (*P* \< 0.05). Addition of sVCAM-1 or α-Endoglin was not able to block the effect of TGFβ3 on *Pdgfa* (**a**) and *Pdgfrα* (**b**) mRNA expression (*P* \< 0.05). \**P* \< 0.05 versus control, ^\#^*P* \< 0.05 versus TGFβ3 stimulation, ^\$^*P* \< 0.05 stimuli versus simultaneous TGFβ3/stimuli. For patterns and abbreviations see Box 1 in [Appendix](#Sec30){ref-type="sec"}

Regulation of proliferation/viability {#Sec22}
-------------------------------------

Several studies showed that TGFβ modulates cell growth and viability. Using an MTT assay, the total number of living cells can be used as a measure for proliferation and viability. We observed that addition of TGFβ reduced the number of living epicardial cells by 31% compared to untreated cells (*P* \< 0.05) (Fig. [9](#Fig9){ref-type="fig"}). The addition of iALK5 and sVCAM-1 increased the number of living epicardial cells by 37 and 130% (*P* \< 0.05), respectively (Fig. [9](#Fig9){ref-type="fig"}). Simultaneously, addition of TGFβ with iALK5 did not affect the number of epicardial cells compared to untreated cells, but there was a significant increase compared to cells treated with TGFβ alone (Fig. [9](#Fig9){ref-type="fig"}). Stimulation with sVCAM-1 was able to prevent the negative effect of TGFβ on the number of living cells completely and the cell number increased by 58% (*P* \< 0.05) after simultaneous addition (Fig. [9](#Fig9){ref-type="fig"}). Inhibition of endoglin (α-Endoglin) significantly increased the number of living epicardial cells by 39% (Fig. [9](#Fig9){ref-type="fig"}). Blocking of endoglin was not able to inhibit the effect of TGFβ, as cells treated simultaneously with TGFβ and α-Endoglin showed significant decrease in cell number by 38.4% (*P* \< 0.05) (Fig. [9](#Fig9){ref-type="fig"}).Fig. 9Quantification of the number of epicardial cells by a MTT assay. TGFβ3 reduced the number of epicardial cells. Stimulation by inhibition of ALK5 (iALK5) and endoglin (α-Endoglin) induced the number of cells, as also did the addition of sVCAM-1. Simultaneous addition of TGFβ3 and iALK5 did not alter cell numbers compared to control and was able to block the effect of TGFβ3. Addition of sVCAM-1 was also able to block the effect of TGFβ3 and significantly increased the total cell number. Inhibition of α-Endoglin was not able to block the effect of TGFβ3 and the number of epicardial cells reduced. \**P* \< 0.05 versus control, ^\#^*P* \< 0.05 versus TGFβ3 stimulation, ^\$^*P* \< 0.05 stimuli versus simultaneous TGFβ3/stimuli. For patterns and abbreviations see Box 1 in [Appendix](#Sec30){ref-type="sec"}

Discussion {#Sec23}
==========

In this study, we show that human adult epicardial cells lose their epithelial character and gain αSMA expression when stimulated by TGFβ. These effects are dependent on ALK5 kinase activity. TGFβ-stimulated loss of epithelial character in adult epicardial cells seems to be independent of endoglin levels, but can be inhibited by induction of VCAM-1. Furthermore, we show that WT1 functions in the regulation of *Pdgfrα* and both have a role in epicardial EMT.

Our data demonstrate a role for the TGFβ/ALK5 signaling pathway in the regulation of EMT of human adult epicardial cells and in the onset of differentiation. The switch from VCAM-1 positive cEPDCs to endoglin expressing sEPDCs is accompanied with downregulation of VCAM-1, which triggers EMT. These new insights into the process of EMT in human adult epicardial cells may help to develop new therapies for cardiac repair, focused on modulation of VCAM-1 and WT1.

Adult EPDCs express VCAM-1 before, but endoglin after, EMT {#Sec24}
----------------------------------------------------------

Epicardial cells isolated from adult atrial appendages changed morphologically during EMT, which was accompanied by a reduction of β-catenin levels. More interestingly, while cEPDCs were characterized by expression of VCAM-1 on their cell surface and an absence of endoglin, sEPDCs did express endoglin and were negative for VCAM-1. Previous studies revealed that VCAM-1 restricts TGFβ-stimulated EMT by inhibiting TGFβ-mediated loss of β-catenin from intercellular junctions and enhances cell--cell adhesion \[[@CR16]\]. Therefore, the expression of VCAM-1 and β-catenin are supportive for the epithelial nature of cEPDCs. Epicardial cells lose their epithelial characteristics under the influence of TGFβ \[[@CR5], [@CR12]\]. Endoglin is an ancillary TGFβ co-receptor expressed on mesenchymal stem cells \[[@CR40]\] and smooth muscle cells \[[@CR10]\] and is involved in EMT \[[@CR13], [@CR43]\]. Together with the decreased expression of β-catenin at the plasma membrane of sEPDCs, endoglin expression in sEPDCs confirms EMT.

Human adult epicardial EMT in vitro {#Sec25}
-----------------------------------

Our data demonstrate that TGFβ-signaling induces loss of epithelial character of human adult cEPDCs and the onset of differentiation toward fibroblasts and/or smooth muscle cells, as previously reported for embryonic mouse and chicken epicardial cells \[[@CR5], [@CR12], [@CR16]\] and human mesothelial epicardial cells \[[@CR15]\]. As TGFβ is expressed in the injured myocardium \[[@CR11], [@CR17], [@CR42]\], reactivated epicardial cells probably undergo EMT and invade into the myocardium due to the local availability of active ligand. In all experimental conditions, human adult epicardial cells also express WT1, confirming their undifferentiated stage.

All human TGFβ isoforms (TGFβ1-3) signal by binding to a heterotetrameric complex of transmembrane serine/threonine kinase receptors \[[@CR21]\]. Upon ligand binding to the TGFβ type II receptor (TGFβRII), the type I receptor (TGFβRI or ALK5) is recruited into the complex and phosphorylated. The activated TGFβRI kinase transduces the signal into the nucleus by phosphorylating Smad proteins required for EMT \[[@CR1], [@CR24]\]. There is a third class of TGFβ receptors, namely the co-receptors β-glycan and endoglin. Addition of TGFβ increased ALK5 expression and decreased the expression of another type I receptor ALK1. Also, the levels of Pai-1 were elevated, a known downstream target of the ALK5/Smad2/3-signaling cascade, and inhibition of the ALK5 kinase decreased Pai-1 expression, also confirming that EMT in human adult epicardial cells is regulated via the TGFβ/ALK5 pathway. Increased expression of ALK5 mRNA after TGFβ stimulation suggests a feed-forward loop.

The addition of TGFβ resulted in decreased number of human adult epicardial cells, suggesting less proliferation or cell viability. Previous studies using endothelial cells (ECs) showed that TGFβ inhibits the proliferation of ECs via the ALK5 pathway, while the ALK1-signaling cascade is responsible for the activation of proliferation \[[@CR22], [@CR27]\]. Although both type 1 receptors are expressed in epicardial cells, only the ALK5 pathway is necessary for TGFβ-induced EMT.

VCAM-1 antagonizes TGFβ-induced EMT in adult epicardial cells {#Sec26}
-------------------------------------------------------------

Soluble VCAM-1 treatment inhibited TGFβ-dependent loss of E-cadherin expression and preserved their epithelial character. Dokic et al. \[[@CR16]\] reported that sVCAM-1 treatment leads to events that increase cortical actin association with the adherens junction and stabilizes adherens junction components at the membrane in embryonic chicken epicardial cells and rat epicardial mesothelial cells (EMCs). The presence of sVCAM-1 stabilizes the cell--cell contacts on the cell membrane, thereby preventing morphological changes. However, the TGFβ-induced decrease in *VCAM*-*1* mRNA expression and the increase of Snai1 mRNA could not be blocked by sVCAM-1. One explanation could be that the change in gene expression and the loss of epithelial character are stimulated via different signaling pathways. In endothelial cells, TGFβ can transduce a signal using two pathways \[[@CR22]\], the TGFβ/ALK5 pathway phosphorylating Smad2/3 and the TGFβ/ALK1 pathway activating Smad1. Interestingly, VCAM-1 is associated with Smad1, as Smad1^−/−^ embryos lack the expression of VCAM-1 in the placenta \[[@CR28]\]. Furthermore, human umbilical vein endothelial cells infected with constitutively active ALK1 increased the expression of VCAM-1, while constitutively active ALK5 reduced its expression \[[@CR37]\]. These observations indicate that the ability of VCAM-1 to alter TGFβ-stimulated EMT probably depends on the stability of adherence junctions, while the TGFβ/ALK5 and TGFβ/ALK1 pathways are involved in regulating the expression of target genes, such as VCAM-1 and Snai1, and regulate the actual process of EMT. Future research needs to demonstrate if, like in endothelial cells, ALK1 is activated upon TGFβ stimulation in epicardial cells, and if sVCAM-1 is able to activate TGFβ/ALK1 signaling. The upregulation of Snai1 seen in simultaneous stimulation of epicardial cells by TGFβ3 and sVCAM-1 is most likely regulated by the ALK5 pathway. Further studies of the signaling pathways altered by VCAM-1 and the modulation of VCAM-1 in human adult epicardial cells should allow us to elucidate the role of VCAM-1 in TGFβ-induced EMT.

The role of endoglin in EMT of adult epicardial cells {#Sec27}
-----------------------------------------------------

The presence of endoglin on the surface of epicardial cells that underwent EMT, suggested a role for endoglin in the process of EMT. This was supported by Mercado-Pimental et al. \[[@CR36]\] who showed that loss of endoglin resulted in a direct perturbation of EMT during cardiac valve formation and reduced the expression of EMT markers including slug and Runx2. However, in our study, blocking of endoglin function by addition of α-Endoglin antibody did not inhibit TGFβ-induced EMT of the EPDCs. One explanation for the discrepancy compared to the study of Mecado-Pimental et al. \[[@CR36]\] is the availability of endoglin for signaling. Using the antibody, we might not be able to occupy all receptors on the cell surface. shRNA knockdown of endoglin in human adult epicardial cells also did not restrict TGFβ-induced morphologic changes in epicardial cells. These data suggest that endoglin is not directly involved in the initiation process of EMT in EPDCs as is shown for endothelial cells \[[@CR27], [@CR39]\], but might be beneficial for differentiation further on in the EMT-pathway.

Wilms tumor suppressor WT1 and Pdgfrα {#Sec28}
-------------------------------------

*WT1* is a novel transcriptional activator of the *α4*-*integrin* gene and stimulation of *α4*-*integrin* expression by WT1 may promote cell adhesion in the epicardium \[[@CR26]\]. Our data show that knockdown of *WT1* in human epicardial cells stimulated the loss of epithelial morphology and reduced expression of E-cadherin, α4-integrin and VCAM-1 significantly, while the expression of Snai1 increased significantly. This suggests that WT1 is a repressor of the EMT process in adult epicardial cells. These findings are consistent with previous described data of Bergmann and Kirschner \[[@CR8], [@CR26]\]. Bergmann et al. described that WT1 transcriptionally represses TGFβ \[[@CR8]\], and Kirschner et al. described that WT1 transcriptionally activates α4-intergrin \[[@CR26]\]. These data are similar to our observation, but opposite to the data described by Martinez-Estrada et al. \[[@CR34]\]. Martinez-Estrada et al. generated immortalized tamoxifen-inducible WT1-knockout epicardial cells (*Cre*+*CoMEEC*, *E11.5*). CoMEECs had typical cobblestone morphology and showed robust WT1 expression. Loss of WT1 after tamoxifen treatment led to a robust increase in E-cadherin expression and was associated with downregulation of N-cadherin, Snai1 and αSMA \[[@CR34]\]. The contradiction between our data and Martinez-Estrada et al. could very well be caused by the fact that EMT in human adult epicardial cells is regulated by other factors compared to EMT in mouse embryonic epicardial cells. Further research is needed to elucidate the exact role of WT1 in the process of EMT in human adult epicardial cells.

Knockdown of *WT1* and *Pdgfrα* \[[@CR7]\] suggested that there was a possible relation between these two factors. Previous study showed that both factors could inhibit the other factor in a significant manner, as *shWT1* increased the *Pdgfrα* expression and *shPdgfrα* increased the expression of *WT1* in human adult epicardial cells \[[@CR7]\]. PDGF-signaling is known to support epicardial EMT. Both PDGF receptors, *Pdgfrα* and *Pdgfrβ*, are expressed in the epicardium \[[@CR6], [@CR35], [@CR47]\]; PDGF-BB, which can bind to both *Pdgfrα* and *Pdgfrβ*, is more potent in inducing cultured embryonic quail epicardial cells to undergo the initial steps of EMT \[[@CR32]\] compared to both PDGF-AA and PDGF-AB, suggesting that this pathway is involved in epicardial EMT. A previous study showed an EMT-inducing role for *Pdgfrα* in mouse embryonic epicardial cells \[[@CR7]\], as the receptor is able to repress WT1 expression. Unpublished data by Smith suggest that both receptors are required for the development of a unique epicardial derivative, *Pdgfrα*, for cardiac fibroblast and *Pdgfrβ* for smooth muscle cells. This is in agreement with earlier observations that show that *Pdgfrα* is more related to myocardial differentiation, while *Pdgfrβ* is expressed during the stage of coronary artery formation \[[@CR48]\]. Furthermore, PDGF-signaling stimulated the phosphorylation of Sox9 and combined with TGFβ induces a transcriptional complex with Smad2 and Snai1 (Smith et al. personal communication). A previous study shows that WT1 is required for Sox9 expression \[[@CR18]\] and that the expression of Sox9 is involved in the process of EMT during cardiac cushion development \[[@CR2]\]. We show that during the process of EMT both WT1 and *Pdgfrα* are involved and more elaborate studies will be necessary to further explore the link between both growth factors and TGFβ, Sox9, Smad2 and Snai1 and their potential roles in human adult epicardial EMT.

Interestingly, a role for PDGF-signaling in EMT is suggested in hepatocarcinogenesis, since PDGF-A ligand and PDGF receptor subunits were highly elevated upon TGFβ-induced EMT \[[@CR20]\]. Our data show that an increase of *Pdgfa* mRNA expression is accompanied by a decrease in *Pdgfrα* expression. This negative relation between PDGF-A and PDGFR-α has been previously described in chicken embryos in which epicardial outgrowth was inhibited \[[@CR6]\]. Furthermore, Paulsson et al. \[[@CR38]\] described that there was a density-dependent inhibitory effect of TGFβ on the expression of *Pdgfrα*. Therefore, our observed TGFβ-regulated decrease of *Pdgfrα* could also be due to an excess of TGFβ-ligand. Future research on the role of *Pdgfrα* mediated by TGFβ and/or WT1 in the EMT process is needed to be able to fully understand this intriguing cascade.

Regenerative medicine {#Sec29}
---------------------

Epicardial cells are a promising tool with regard to cardiac regeneration therapy. Transplantation of exogenous human adult EPDCs into the ischemic mouse myocardium improved left ventricular (LV) ejection fraction. Adverse remodeling was also attenuated by EPDCs injection \[[@CR52]\]. The importance of epicardial cells and EPDCs for cardiogenesis and regenerative medicine is related to their role in coronary vessel development and maintenance of myocardial architecture \[[@CR19], [@CR29], [@CR31], [@CR44], [@CR52]\]. Activation of endogenous epicardium stimulates the process of EMT, by which cells can migrate into the myocardium. Reactivation of the embryonic program of epicardial cells after myocardial injury is of great importance for the process of intrinsic cardiac repair. Understanding more of the process of EMT and the involved pathways in human adult epicardial cells is important for the development of strategies to stimulate heart repair by endogenous cell sources.

The members of the TGFβ superfamily are markedly induced in the infarcted myocardium and through their potent effects are capable of playing a central role in infarct healing and cardiac repair \[[@CR11], [@CR17], [@CR42]\]. Our data combined with previous studies suggest that TGFβ is not only a central mediator involved in the inflammatory and fibrotic phase of healing and may critically modulate many cellular steps in post-infarction cardiac repair \[[@CR11], [@CR17], [@CR42]\], but can also induce EMT of epicardial cells.

Thymosin beta 4 (Tβ4) is reported to activate endogenous mouse adult epicardium after myocardial infarction \[[@CR41], [@CR44]\]. This, combined with the knowledge from previous studies that Tβ4 significantly increase the expression of TGFβ \[[@CR9]\] and that Tβ4 increases the secretion of Pai-1 in endothelial cells \[[@CR3]\], suggests that Tβ4 could be the initiator for the onset of the EMT-regulated pathway in adult epicardial cells (Fig. [10](#Fig10){ref-type="fig"}). Therefore, Tβ4 might elevate TGFβ, thereby inducing EMT of epicardial cells and it would be very interesting to see if the effects of TGFβ on VCAM-1, WT1 and *Pdgfrα* during EMT in human adult epicardial cells are initiated by Tβ4. Future research in cardiac repair, focusing on the potential of the TGFβ/ALK5 pathway initiating EMT of endogenous human adult epicardial cells investigation via transcriptional regulation of WT1 and *Pdgfrα*, might provide new treatment modalities.Fig. 10Epithelial-to-mesenchymal transformation (EMT) of human adult epicardial cells. Master regulator of EMT, Snai1, leads to dramatic changes in gene expression profile and cellular morphology. Snai1 represses the expression of epithelial markers and triggers the expression of EMT markers. Herewith, we depict a possible pathway, which stimulates epicardial EMT after myocardial injury (adapted from Kang et al. \[[@CR25]\]. *Arrows with arrowheads* represent activation and *arrows with bullets* represent repression. *Dashed arrow lines with arrowheads and bullets* represent indicative pathways
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###### 

**Online Resource 1. Expression of ALK1 in epicardial cells**. Quantitative PCR on RNA of cEPDCs (control; C) and epicardial cells treated with 1 ng/ml TGFβ3 (T) showed that the expression of *ALK1* was decreased by TGFβ3. (TIFF 596 kb)

###### 

**Online Resource 2. Expression of TGFβ-isoforms in epicardial cells**. Quantitative PCR on RNA of epicardial cells and epicardial cells incubated with iALK5, α-Endoglin and sVCAM-1 in the presence or absence of TGFβ3 showed that the expression of *TGFβ1* (a) and *TGFβ2* (b) mRNA was significantly reduced in the presence of iALK (P \< 0.05). The addition of TGFβ3 reduced the mRNA of *TGFβ3* mRNA significantly (P \< 0.05) (c). Addition of iALK5 in the presence of TGFβ3 was able to inhibit the decrease in *TGFβ3* mRNA expression stimulated by TGFβ3, while addition of sVCAM-1 was not. For patterns and abbreviations see Box 1 in the main article. (TIFF 1311 kb)

###### 

**Online Resource 3. The role of RhoA kinase EMT of adult epicardial cells**. Inhibition of p160 Rho kinase activity caused elongation of epicardial cells (a1), which was accompanied by reduction in β-catenin (a2) staining, but there was no induction of stress fibers and αSMA (a3,4). Addition of iROCK in the presence of TGFβ was not able to prevent loss in epithelial character (b1); this was accompanied by increased expression of β-catenin and phalloidin (b2,3). Scale bar, 20 μm. (TIFF 11082 kb)

###### 

**Online Resource 4. Role of WT1 in the process of EMT**. Quantification of *WT1* isoform D mRNA expression in human adult epicardial cells after treatment with knockdown of *WT1* by shRNA results in significantly reduced expression of *WT1isoD*. For patterns and abbreviations see Box 1 in the main article. (TIFF 198 kb)
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Box 1Patterns and abbreviations
